OGN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally...

Stats
Today's Volume	2.00M
Average Volume	2.36M
Market Cap	4.78B
EPS	$0 ( 2024-02-15 )
Next earnings date	( $0.970 ) 2024-05-02
Last Dividend	$0.280 ( 2023-11-10 )
Next Dividend	$0 ( N/A )
P/E	4.69
ATR14	$0.0200 (0.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-29	Arjona Ferreira Juan Camilo	Buy	108 932	Stock Option (right to buy)
2024-03-29	Arjona Ferreira Juan Camilo	Buy	26 595	Restricted Stock Units
2024-03-31	Morrissey Joseph T. Jr.	Buy	7 794	Common Stock
2024-03-31	Morrissey Joseph T. Jr.	Sell	2 328	Common Stock
2024-03-31	Morrissey Joseph T. Jr.	Buy	3 936	Common Stock

INSIDER POWER
64.90
Last 100 transactions
Buy: 2 246 661 \| Sell: 486 702

Volume Correlation

Long: 0.50 (weak)

Short: 0.01 (neutral)

Signal:(65.84) Neutral

Organon & Co. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Organon & Co. Correlation - Currency/Commodity

0.63
( weak )

-0.04
( neutral )

0.00
( neutral )

0.41
( neutral )

-0.76
( moderate negative )

0.07
( neutral )

Organon & Co. Financials

Annual	2023
Revenue:	$6.26B
Gross Profit:	$3.75B (59.84 %)
EPS:	$4.01

Q4	2023
Revenue:	$1.60B
Gross Profit:	$915.00M (57.26 %)
EPS:	$2.14

Q3	2023
Revenue:	$1.52B
Gross Profit:	$907.00M (59.71 %)
EPS:	$0.230

Q2	2023
Revenue:	$1.61B
Gross Profit:	$968.00M (60.20 %)
EPS:	$0.950

Financial Reports:

No articles found.

Organon & Co. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.280 (N/A)	$0.280 (N/A)	$0.280 (N/A)	$0.280 (N/A)	$0.280 (N/A)	$0.280 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Organon & Co. Dividend Information - Dividend Knight

Dividend Sustainability Score: 7.83 - good (78.32%) | Divividend Growth Potential Score: 4.25 - Stable (14.92%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.280	2021-08-20
Last Dividend	$0.280	2023-11-10
Next Dividend	$0	N/A
Payout Date	2023-12-14
Next Payout Date	N/A
# dividends	10	--
Total Paid Out	$2.80	--
Avg. Dividend % Per Year	2.08%	--
Score	4.25	--
Div. Sustainability Score	7.83
Div.Growth Potential Score	4.25
Div. Directional Score	6.04	--

Next Divdend (Est)
(2024-07-01)

$0.285 Estimate 37.78 %

Dividend Stability

0.76 Good

Dividend Score

4.25

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2021	$0.560	1.68%
2022	$1.120	3.59%
2023	$1.120	3.99%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
ORC	Dividend Royal	2023-11-29	Monthly	12	9.23%	8.50
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
NCZ	Dividend Royal	2024-02-09	Monthly	22	7.79%	8.50
SCM	Dividend King	2023-12-15	Monthly	13	7.08%	8.50
SJT	Dividend Royal	2023-11-29	Monthly	39	12.52%	8.50
SRV	Dividend Royal	2023-12-04	Monthly	18	7.53%	8.50
VGI	Dividend Royal	2024-02-09	Monthly	13	7.36%	8.50
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.163	1.500	6.73	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0848	1.200	7.17	8.61	[0 - 0.3]
returnOnEquityTTM	-2.10	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0.287	-1.000	7.13	-7.13	[0 - 1]
currentRatioTTM	1.545	0.800	7.28	5.82	[1 - 3]
quickRatioTTM	0.835	0.800	9.79	7.83	[0.8 - 2.5]
cashRatioTTM	0.237	1.500	9.79	10.00	[0.2 - 2]
debtRatioTTM	0.726	-1.500	10.00	-10.00	[0 - 0.6]
interestCoverageTTM	1.221	1.000	-0.659	-0.659	[3 - 30]
operatingCashFlowPerShareTTM	3.13	2.00	8.96	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.10	2.00	8.95	10.00	[0 - 20]
debtEquityRatioTTM	-125.14	-1.500	-10.00	10.00	[0 - 2.5]
grossProfitMarginTTM	0.598	1.000	3.36	3.36	[0.2 - 0.8]
operatingProfitMarginTTM	0.103	1.000	9.94	9.94	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.0912	1.000	-0.604	-0.604	[0.2 - 2]
assetTurnoverTTM	0.519	0.800	9.87	7.90	[0.5 - 2]
Total Score				7.83

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	4.63	1.000	9.63	0	[1 - 100]
returnOnEquityTTM	-2.10	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.10	2.00	9.30	10.00	[0 - 30]
dividendYielPercentageTTM	6.05	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	3.13	2.00	8.96	10.00	[0 - 30]
payoutRatioTTM	0.287	1.500	7.13	-7.13	[0 - 1]
pegRatioTTM	-0.140	1.500	-4.27	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.128	1.000	9.31	0	[0.1 - 0.5]
Total Score				4.25

Organon & Co.

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.